Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Express Scripts
Boehringer Ingelheim

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,529,593

« Back to Dashboard

Summary for Patent: 4,529,593

Title: Use of gallium salts to treat disorders of calcium homeostasis
Abstract:The present invention comprises a method of preventing or treating a disorder associated with accelerated loss of calcium from bone in a human individual comprising administering to the individual a pharmaceutically acceptable gallium compound. Of especial importance among the disorders which may be thus prevented or treated are hypercalcemia, accelerated bone loss associated with osteopenia, osteoporosis, bone metastasis due to malignant tumors, and hyperparathyroidism. In the method of the present invention gallium compounds may be administered by any and all routes. Although all biocompatible, soluble compounds of gallium may be used in the present invention, gallium nitrate is preferred, most preferably in a pharmaceutically acceptable carrier.
Inventor(s): Warrell, Jr.; Raymond P. (New York, NY), Bockman; Richard S. (New York, NY)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:06/622,726
Patent Claim Types:
see list of patent claims
Use; Compound; Composition; Formulation; Delivery;

No matches for this query

International Patent Family for Patent: 4,529,593

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada1219210► Subscribe
Germany3376387► Subscribe
European Patent Office0109564► Subscribe
JapanH0261924► Subscribe
JapanS59205322► Subscribe
JapanS6112625► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: